Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human papillomavirus bivalent (types 16 and 18) vaccine
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This recombinant human papillomavirus bivalent vaccine targets types 16 and 18 of the Human Papillomavirus. It is designed to evaluate its safety and immunogenicity in healthy females aged 9-45 years. The vaccine is administered via a three-dose schedule (0, 2, 6 months) and aims to induce an immune response, specifically neutralizing antibodies, against HPV types 16 and 18. The recombinant proteins are produced in yeast.
- Brand names
- Cervarix
- Other names
- HPV-16/18 L1/AS04 vaccinebivalent HPV vaccineHPV 16/18 vaccinehuman papillomavirus bivalent (types 16 and 18) vaccine, recombinant
02
Targets
HPV16 (Human papillomavirus type 16)HPV18 L1TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on recombinant human papillomavirus bivalent (types 16 and 18) vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human papillomavirus bivalent (types 16 and 18) vaccine.